GPD2

Across TCGA pan-cancer cohorts, GPD2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GPD2 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GPD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GPD2 expression acts as an unfavorable survival marker, although some lineages such as COAD and HNSC show a favorable association.

CCRCC, COAD, and LUAD are the cancer types where GPD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.261	0.708	.014	45	view →
COAD	DFS	Tertile	II,III,IV	1.000	0.862	.032	30	view →
LUAD	DFS	Quartile	All	0.328	0.762	.002	14	view →
HNSC	DFS	Quartile	IV	0.854	0.566	.008	4	view →
PDAC	DFS	Tertile	IV	0.205	0.741	.024	3	view →
GBM	DFS	Median	All	0.460	0.288	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GPD2–CCRCC (DFS)

Open the CCRCC breakdown →